Background Accurate detection and determination of axillary lymph node metastasis are crucial for the clinical management of patients with breast cancer. Noninvasive imaging methods including ultrasound (US), computed tomography (CT), or conventional magnetic resonance imaging (MRI) are not yet accurate enough. The purpose of this study was to investigate the value of in vivo T2* in differentiating metastatic from benign axillary lymph nodes in patients with breast cancer. Methodology/Principal Findings In this institutional review board approved study, 35 women with breast cancer underwent multi-echo T2* weighted imaging (T2*WI) of the axillary area on a 3.0 T clinical magnetic resonance (MR) imaging system. T2* values of pathologically proven benign and metastatic axillary lymph nodes were calculated and compared. Receiver operating characteristics (ROC) analysis was conducted to evaluate the diagnostic ability. The areas under the ROC curve (AUCs) and the confidence intervals (CIs) were assessed. In total, 56 metastatic and 65 benign axillary lymph nodes were identified in this study. For metastatic lymph nodes, the average T2* value (55.96±11.87 ms) was significantly longer than that of the benign lymph nodes (26.00±5.51 ms, P<0.05). The AUC of T2* in differentiating benign from metastatic lymph nodes was 0.993. The cut-off value of 37.5 milliseconds (ms) gave a sensitivity of 94.6%, a specificity of 98.5%, a positive predictive value of 98.17 and a negative predictive value 95.54. Conclusions In vivo T2* can differentiate benign from metastatic axillary lymph nodes in patients with breast cancer. The high sensitivity and specificity as well as the easiness suggest its high potential for use in clinical practice.
References
[1]
Tolaney SM, Winer EP (2007) Follow-up care of patients with breast cancer. Breast 16(Suppl 2): S45–50.
[2]
Le Bouedec G, Gauthier T, Gimbergues P, Dauplat J (2008) Axillary recurrence after negative sentinel lymph node biopsy in breast cancer. Presse Med 37: 1685–1687.
[3]
Strnad P, Rob L, Krízová H, Zuntová A, Chod J, et al. (2005) Sentinel lymphatic node biopsy for breast cancer in practice. Ceska Gynekol 70: 291–295.
[4]
Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, et al. (2003) Axillary Lymph Node Status, But Not Tumor Size, Predicts Locoregional Recurrence and Overall Survival After Mastectomy for Breast Cancer. Ann Surg 237: 732–739.
[5]
McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, et al. (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26: 5213–5219.
[6]
Vassallo P, Edel G, Roos N, Naguib A, Peters PE (1993) In-vitro high-resolution ultrasonography of benign and malignant lymph nodes. A sonographic-pathologic correlation. Invest Radiol 28: 698–705.
[7]
Dooms GC, Hricak H, Crooks LE, Higgins CB (1984) Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 153: 719–728.
[8]
Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, et al. (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8: 165.
[9]
Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, et al. (2011) Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess 15: 1–134.
[10]
Mortellaro VE, Marshall J, Singer L, Hochwald SN, Chang M, et al. (2009) Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 30: 309–312.
[11]
Murray AD, Staff RT, Redpath TW, Gilbert FJ, Ah-See AK, et al. (2002) Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes. Br J Radiol 75: 220–228.
[12]
Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, et al. (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37: 1077–1086.
[13]
Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I (2007) Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 63: 401–407.
[14]
Lim SW, Kim HW, Jun HY, Park SH, Yoon KH, et al. (2011) TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol 18: 504–511.
[15]
Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I (2007) Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. European Journal of Radiology 63: 401–407.
[16]
Korteweg MA, Zwanenburg JJ, Hoogduin JM, van den Bosch MA, van Diest PJ, et al. (2011) Dissected Sentinel Lymph Nodes of Breast Cancer Patients: Characterization with High-Spatial-Resolution 7-T MR Imaging. Radiology 261: 127–135.
[17]
He N, Xie C, Wei W, Pan C, Wang W, et al. (2012) A new, preoperative, MRI-based scoring system for diagnosing malignant axillary lymph nodes in women evaluated for breast cancer. Eur J Radiol 81: 2602–2612.
[18]
Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9: 606–616.
[19]
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, et al. (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305: 569–575.
[20]
Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, et al. (1992) Assessment of morbidity from complete axillary dissection. Br J Cancer 66: 136–138.
[21]
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, et al. (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98: 599–609.
[22]
Lale Atahan I, Yildiz F, Ozyigit G, Sari S, Gurkaynak M, et al. (2008) Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol 47: 232–238.
[23]
Hildebrandt MG, Bartram P, Bak M, H？jlund-Carlsen M, Petersen H, et al. (2011) Low risk of recurrence in breast cancer with negative sentinel node. Dan Med Bull 58: A4255.
[24]
Martin RC 2nd, Chagpar A, Scoggins CR, Edwards MJ, Hagendoorn L, et al. (2005) Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 241: 1005–1012.
[25]
Bahri S, Chen JH, Yu HJ, Kuzucan A, Nalcioglu O, et al. (2008) Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer? Ann Oncol 19: 822–824.
[26]
Kvistad KA, Rydland J, Smethurst HB, Lundgren S, Fj？sne HE, et al. (2000) Axillary lymph node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol 10: 1464–1471.
[27]
Kwee TC, Takahara T, Luijten PR, Nievelstein RA (2010) ADC measurements of lymph nodes: inter-and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 75: 215–220.
[28]
Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, et al. (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37: 1077–1086.
[29]
Scaranelo AM, Eiada R, Jacks LM, Kulkarni SR, Crystal P (2012) Accuracy of unenhanced MR imaging in the detection of axillary lymph node metastasis: study of reproducibility and reliability. Radiology 262: 425–434.
[30]
Luciani A, Pigneur F, Ghozali F, Dao TH, Cunin P, et al. (2009) Ex vivo MRI of axillary lymph nodes in breast cancer. European Journal of Radiology 69: 59–66.
[31]
Zuo CS, Sung YH, Simonson DC, Habecker E, Wang J, et al. (2012) Reduced T2* values in soleus muscle of patients with type 2 diabetes mellitus. PLoS One 7: e49337.
